Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
InnoCare Pharma Ltd. ( (HK:9969) ) has provided an update.
InnoCare Pharma has scheduled a board meeting for 23 April 2026 to review and approve its unaudited first-quarter results for the period ended 31 March 2026. The move signals that the company is preparing to publish its latest financial performance, an important disclosure for investors tracking its operational progress and market trajectory.
The board, led by chairperson and executive director Dr. Jisong Cui, will consider these results alongside other corporate matters at the meeting. The announcement underlines the company’s adherence to Hong Kong listing requirements on timely financial reporting and provides stakeholders with a clear timeline for forthcoming earnings information.
The most recent analyst rating on (HK:9969) stock is a Buy with a HK$16.50 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
More about InnoCare Pharma Ltd.
InnoCare Pharma Limited is a biotechnology company listed in Hong Kong that focuses on pharmaceutical research and development. The company operates through a board structure comprising executive, non-executive and independent non-executive directors, reflecting a typical governance framework for a Hong Kong–listed pharma issuer.
Average Trading Volume: 7,816,271
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$22.67B
See more data about 9969 stock on TipRanks’ Stock Analysis page.